Showing 341 - 360 results of 892 for search '((((ill OR (fill OR hill)) OR ((thtfill OR thtfill) OR thfhill)) OR all) OR wall) (funding)', query time: 0.16s Refine Results
  1. 341

    Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial by Silk, SE, Kalinga, WF, Salkeld, J, Mtaka, IM, Ahmed, S, Milando, F, Diouf, A, Bundi, CK, Balige, N, Hassan, O, Mkindi, CG, Rwezaula, S, Athumani, T, Mswata, S, Lilolime, NS, Simon, B, Msami, H, Mohamed, M, David, DM, Mohammed, L, Nyaulingo, G, Mwalimu, B, Juma, O, Mwamlima, TG, Sasamalo, IA, Mkumbange, RP, Kamage, JJ, Barrett, JR, King, LDW, Hou, MM, Pulido, D, Carnrot, C, Lawrie, AM, Cowan, RE, Nugent, FL, Roberts, R, Cho, J-S, Long, CA, Nielsen, CM, Miura, K, Draper, SJ, Olotu, AI, Minassian, AM

    Published 2024
    “…We found similar functional quality (ie, GIA per μg RH5-specific IgG) across all age groups and dosing regimens at 14 days after the final vaccination; the concentration of RH5.1-specific polyclonal IgG required to give 50% GIA was 14·3 μg/mL (95% CI 13·4–15·2). 11 children were vaccinated with the delayed third dose regimen and showed the highest median anti-RH5 serum IgG concentration 14 days following the third vaccination (723 μg/mL [IQR 511–1000]), resulting in all 11 who received the full series showing greater than 60% GIA following dilution of total IgG to 2·5 mg/mL (median 88% [IQR 81–94]).…”
    Journal article
  2. 342
  3. 343
  4. 344
  5. 345
  6. 346
  7. 347
  8. 348
  9. 349
  10. 350
  11. 351
  12. 352
  13. 353
  14. 354
  15. 355
  16. 356
  17. 357
  18. 358
  19. 359
  20. 360